BRPI9908914A - composto de ferro-dextrana para uso como um componente em uma composição terapêutica, para profilaxia ou tratamento de deficiência de ferro; processo para a produção do referido composto de ferro-dextrana e uso do referido composto para preparação de uma composição terapêutica parenteralmente administrável. - Google Patents

composto de ferro-dextrana para uso como um componente em uma composição terapêutica, para profilaxia ou tratamento de deficiência de ferro; processo para a produção do referido composto de ferro-dextrana e uso do referido composto para preparação de uma composição terapêutica parenteralmente administrável.

Info

Publication number
BRPI9908914A
BRPI9908914A BRPI9908914A BRPI9908914A BRPI9908914A BR PI9908914 A BRPI9908914 A BR PI9908914A BR PI9908914 A BRPI9908914 A BR PI9908914A BR PI9908914 A BRPI9908914 A BR PI9908914A BR PI9908914 A BRPI9908914 A BR PI9908914A
Authority
BR
Brazil
Prior art keywords
dextran
iron
compound
daltons
therapeutic composition
Prior art date
Application number
BRPI9908914A
Other languages
English (en)
Inventor
Hans Berg Andreasen
Lars Christensen
Original Assignee
Pharmacosmos Holding As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8093321&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9908914(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacosmos Holding As filed Critical Pharmacosmos Holding As
Publication of BRPI9908914A publication Critical patent/BRPI9908914A/pt
Publication of BRPI9908914B1 publication Critical patent/BRPI9908914B1/pt
Publication of BRPI9908914B8 publication Critical patent/BRPI9908914B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

"composto de ferro-dextrana para uso como um componente em uma composição terapêutica, para profilaxia ou tratamento de deficiência de ferro; processo para a produção do referido composto de ferro-dextrana e uso do referido composto para preparação de uma composição terapêutica parenteralmente administrável" trata-se de um composto de ferro-dextrana, para tratamento parenteral de anemia por deficiência de ferro, compreende dextrana hidrogenada, tendo um peso molecular de média ponderal (mw) entre 700 e 1.400 daltons, de preferência aproximadamente, 1.000 daltons, um peso molecular médio númérico (mn) de 400 a 1.400 daltons, e em que 90 % do peso da dextrana tenha pesos moleculares menores do que 2.700 daltons e que o mw de 10 % em peso da fração de dextrana com peso molecular mais alto esteja abaixo de 3.200 daltons, tendo a referida dextrana hidrogenada sido submetida à purificação por um processo de membrana, com um valor de corte entre 340 e 800 daltons, em associação estável com oxi-hidróxido férrico. o composto é produzido através de um processo com membrana para eliminar dextranas de pesos moleculares mais altos do que, aproximadamente, 2.700 daltons, e um processo com membrana para remover sacarídeos de pesos moleculares menores do que, aproximadamente, 340 daltons de dextrana hidrogenada, antes da precipitação do hidróxido férrico na presença da referida dextrana, seguido por aquecimento e purificação.
BRPI9908914 1998-03-25 1999-03-24 composto de ferro-dextrana para uso como um componente em uma composiÇço terapÊutica, para profilaxia ou tratamento de deficiÊncia de ferro; processo para a produÇço do referido composto de ferro-dextrana e uso do referido composto para preparaÇço de uma composiÇço terapÊutica parenteralmente administrÁvel. BRPI9908914B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK199800420A DK172860B1 (da) 1998-03-25 1998-03-25 Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
PCT/DK1999/000160 WO1999048533A1 (en) 1998-03-25 1999-03-24 An iron-dextran compound for use as a component in a therapeutical composition for prophylaxis or treatment of iron-deficiency, a process for producing said iron-dextran compound and use of said compound for the preparation of a parenterally administrable therapeutical composition

Publications (3)

Publication Number Publication Date
BRPI9908914A true BRPI9908914A (pt) 2000-11-21
BRPI9908914B1 BRPI9908914B1 (pt) 2012-06-12
BRPI9908914B8 BRPI9908914B8 (pt) 2021-07-06

Family

ID=8093321

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9908914 BRPI9908914B8 (pt) 1998-03-25 1999-03-24 composto de ferro-dextrana para uso como um componente em uma composiÇço terapÊutica, para profilaxia ou tratamento de deficiÊncia de ferro; processo para a produÇço do referido composto de ferro-dextrana e uso do referido composto para preparaÇço de uma composiÇço terapÊutica parenteralmente administrÁvel.

Country Status (28)

Country Link
US (1) US6291440B1 (pt)
EP (1) EP1066056B2 (pt)
JP (1) JP4558198B2 (pt)
KR (1) KR100612071B1 (pt)
CN (1) CN1147322C (pt)
AR (1) AR015738A1 (pt)
AT (1) ATE220560T1 (pt)
AU (1) AU740432B2 (pt)
BR (1) BRPI9908914B8 (pt)
CA (1) CA2322633C (pt)
CZ (1) CZ300823B6 (pt)
DE (1) DE69902154T3 (pt)
DK (2) DK172860B1 (pt)
EA (1) EA003427B1 (pt)
ES (1) ES2180279T5 (pt)
HK (1) HK1033426A1 (pt)
HU (1) HU228483B1 (pt)
ID (1) ID26778A (pt)
NO (1) NO329591B1 (pt)
NZ (1) NZ505983A (pt)
PL (1) PL195582B1 (pt)
PT (1) PT1066056E (pt)
SI (1) SI1066056T2 (pt)
SK (1) SK284499B6 (pt)
TR (1) TR200002733T2 (pt)
UA (1) UA70939C2 (pt)
WO (1) WO1999048533A1 (pt)
ZA (1) ZA200004016B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173138B1 (da) 1998-11-20 2000-02-07 Pharmacosmos Holding As Fremgangsmåde til fremstilling af en jerndextranforbindelse, jerndextranforbindelse fremstillet efter fremgangsmåden, farma
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
DE60043188D1 (de) * 1999-04-09 2009-12-03 Amag Pharmaceuticals Inc Hitzebeständige umhüllte kolloidale eisenoxide
KR20020003344A (ko) * 2001-12-17 2002-01-12 유형선 철분 보급제 경구 투여 제제 조성물
BR0308773A (pt) * 2002-04-09 2005-02-09 Pharmacosmos Holding As Compostos de dextrina de ferro para tratamento de anemia por deficiência de ferro
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US20060116349A1 (en) * 2003-03-14 2006-06-01 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron for the treatment of restless leg syndrome
DE102004031181A1 (de) * 2004-06-28 2006-01-19 Vifor (International) Ag Phosphatadsorbens
ITMO20050056A1 (it) * 2005-03-15 2006-09-16 Biofer Spa Processo per la preparazione di complessi del ferro trivalente con zuccheri mono-, di- e polisaccaridi.
EP1757299A1 (de) 2005-08-25 2007-02-28 Vifor (International) Ag Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung
EP2626074A1 (en) 2006-01-06 2013-08-14 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
EP1947120A1 (de) * 2007-01-19 2008-07-23 Vifor (International) Ag Eisen-Kohlenhydrat-Komplex-Verbindungen
EP1997833A1 (de) * 2007-05-29 2008-12-03 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydratderivat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
CN101585887B (zh) * 2008-05-22 2011-12-14 中国科学院过程工程研究所 应用纳滤技术对右旋糖酐铁络合物水溶液进行脱盐和浓缩的方法
EP3156075B1 (en) 2009-03-25 2020-10-14 Pharmacosmos Holding A/S An oligosaccharide and a process for preparation thereof
CN101967205B (zh) * 2010-10-12 2013-04-17 滨州学院 一种β-葡聚糖铁复合物及其制备方法
EP2537866A1 (en) 2011-06-21 2012-12-26 Serumwerk Bernburg AG Hydroxyethyl starch derivatives, method for manufacturing the same and therapeutical uses thereof
PL398814A1 (pl) 2012-04-16 2013-10-28 Uniwersytet Jagiellonski Zastosowanie pochodnych dekstranu do przeciwdzialania lub leczenia niedokrwistosci
US10172882B2 (en) 2014-06-22 2019-01-08 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
HUE045092T2 (hu) * 2014-10-27 2019-12-30 Pharmacosmos Holding As Vérszegénység kezelése vagy megelõzése vemhes nem-humán emlõsökben és utódaikban
JP7426927B2 (ja) 2017-09-11 2024-02-02 ファーマコスモス ホールディング エー/エス 治療的使用のための鉄錯体化合
CN109646454A (zh) * 2018-12-29 2019-04-19 博瑞生物医药(苏州)股份有限公司 异麦芽糖酐铁1000的制备方法
CN110183548B (zh) * 2019-06-28 2021-05-18 瑞普(天津)生物药业有限公司 一种低分子葡聚糖铁的制备方法及其应用
BR112024002150A2 (pt) 2021-08-03 2024-04-30 Pharmacosmos Holding As Compostos de complexo de ferro para uso subcutâneo na terapia de deficiência de ferro em animais de companhia

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE24642E (en) 1959-04-28 Therapeutic preparations of iron
DK117730A (pt)
US2885393A (en) 1956-02-24 1959-05-05 R K Laros Company Dextran-iron complex and process for making same
US3093545A (en) 1960-08-29 1963-06-11 Armour Pharma Therapeutic iron-dextran preparations
US3234209A (en) * 1963-09-13 1966-02-08 Chemicals Inc Process for making iron hydrogenated dextran
DE1293144B (de) * 1964-11-04 1969-04-24 Hausmann Ag Labor Verfahren zur Herstellung von Komplexverbindungen des Eisens mit Sorbit, Gluconsaeure und einem Oligosaccharid
GB1183940A (en) 1966-10-22 1970-03-11 Fisons Pharmaceuticals Ltd Ferric Hydroxide Complexes
GB1200902A (en) 1967-05-13 1970-08-05 Fisons Pharmaceuticals Ltd Iron-dextran complexes
CH507993A (de) 1967-07-13 1971-05-31 Kutnowskie Zakl Farma Verfahren zur Herstellung von Eisen(III)-komplexverbindungen mit hydriertem Dextran
DK129353B (da) 1968-04-29 1974-09-30 Fisons Pharmaceuticals Ltd Analogifremgangsmåde til fremstilling af et ferrihydroxid-dextranderivatkompleks eller en opløsning deraf.
US3697502A (en) 1969-11-03 1972-10-10 Christensen Henry M Method of making iron dextran-preparations
GB1562913A (en) * 1976-06-16 1980-03-19 Fisons Ltd Fractionating fluid mixtures of dextrans
DE3422249A1 (de) * 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Wasserloesliches eisendextran und verfahren zu seiner herstellung
US4827945A (en) 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5102652A (en) * 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
IT1263831B (it) * 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
RU2093577C1 (ru) * 1993-11-04 1997-10-20 Государственный институт кровезаменителей и медицинских препаратов Способ получения декстрана
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
US5624668A (en) * 1995-09-29 1997-04-29 Luitpold Pharmaceuticals, Inc. Iron dextran formulations

Also Published As

Publication number Publication date
BRPI9908914B1 (pt) 2012-06-12
NO20004151D0 (no) 2000-08-18
NO329591B1 (no) 2010-11-15
DE69902154D1 (de) 2002-08-22
US6291440B1 (en) 2001-09-18
SI1066056T2 (sl) 2009-04-30
ATE220560T1 (de) 2002-08-15
EA003427B1 (ru) 2003-04-24
DK1066056T4 (da) 2009-04-14
CA2322633A1 (en) 1999-09-30
UA70939C2 (uk) 2004-11-15
ES2180279T5 (es) 2009-05-05
EA200000981A1 (ru) 2001-02-26
EP1066056A1 (en) 2001-01-10
SI1066056T1 (en) 2002-12-31
NO20004151L (no) 2000-08-18
PL343164A1 (en) 2001-07-30
ES2180279T3 (es) 2003-02-01
DK172860B1 (da) 1999-08-16
SK14092000A3 (sk) 2001-04-09
CN1147322C (zh) 2004-04-28
DK1066056T3 (da) 2002-10-14
AU2827399A (en) 1999-10-18
KR100612071B1 (ko) 2006-08-11
EP1066056B2 (en) 2008-12-10
HK1033426A1 (en) 2001-08-31
CA2322633C (en) 2009-01-27
AR015738A1 (es) 2001-05-16
ID26778A (id) 2001-02-08
ZA200004016B (en) 2001-07-25
JP4558198B2 (ja) 2010-10-06
CN1293577A (zh) 2001-05-02
HUP0101189A2 (hu) 2001-08-28
SK284499B6 (sk) 2005-05-05
PT1066056E (pt) 2002-12-31
DK42099A (da) 1999-08-16
DE69902154T2 (de) 2003-03-06
NZ505983A (en) 2002-11-26
WO1999048533A1 (en) 1999-09-30
KR20010034641A (ko) 2001-04-25
CZ300823B6 (cs) 2009-08-19
JP2002507582A (ja) 2002-03-12
HUP0101189A3 (en) 2003-12-29
TR200002733T2 (tr) 2000-12-21
AU740432B2 (en) 2001-11-01
DE69902154T3 (de) 2009-07-09
EP1066056B1 (en) 2002-07-17
CZ20003535A3 (cs) 2001-04-11
PL195582B1 (pl) 2007-10-31
HU228483B1 (en) 2013-03-28
BRPI9908914B8 (pt) 2021-07-06

Similar Documents

Publication Publication Date Title
BRPI9908914A (pt) composto de ferro-dextrana para uso como um componente em uma composição terapêutica, para profilaxia ou tratamento de deficiência de ferro; processo para a produção do referido composto de ferro-dextrana e uso do referido composto para preparação de uma composição terapêutica parenteralmente administrável.
BR9405353A (pt) Agente para tratamento dos cabelos
NZ315275A (en) Inhalant composition including ultra low mw heparins (ULMWH) to treat asthma
BRPI9909282A (pt) compostos de éter aminociclohexílicos e usos dos mesmos.
TW357196B (en) Corrosion resistant treatment for metal surfaces
BR9807315A (pt) Ligas de copolìmero de polipropileno e processo para a preparação
BR0010575A (pt) Composição de amaciamento de tecido, e, método de depositar um agente de amaciamento de tecido não iÈnico no tecido de uma composição de amaciamento de tecido
BR0210568A (pt) Conjugado, uso de um conjugado, composição farmacêutica, e, método para tratar câncer em um mamìfero
BR0010380A (pt) Método, composição farmacêutica, kit e uso de uma combinação para prevenção e tratamento de diversas disfunções tromboembólicas e métodos de tratamento de trombose em mamìferos
BR0212374A (pt) Oxintomodulina para a prevenção ou para o tratamento do excesso de peso
BR9913383A (pt) Pirazol-carboxanilidas
NZ333925A (en) Use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus
DE69621813T2 (de) Eisen-dextran formulierungen
WO2000074662A3 (en) Arthritis treatment
BR0214716A (pt) Contraceptivos para prevenção de gravidez e diminuição de sintomatologia pré-menstrual
BR9904808A (pt) Tubagem médica em monocamada de baixo módulo, esterilizável em autoclave
BR0211852A (pt) Polìmeros aromáticos de monovinilideno baseados em borrachas de polibutadieno de peso molecular elevado altamente lineares e um processo para sua preparação
DK1269860T3 (da) Farmaceutisk præparat
BR9916487A (pt) Sistema de cola não-aquoso para fibras de vidro epolìmeros moldáveis por injeção
BR9812660A (pt) Composições e métodos para tratar distúrbios respiratórios
BR0207919A (pt) Método para a preparação de uma micropartìcula homogênea de metoprolol, micropartìcula, composição farmacêutica, método para prevenir ou tratar um distúrbio cardiovascular em um mamìfero, e, uso de uma micropartìcula
BR0016383A (pt) Polìmeros aromáticos de monovinilideno com propriedades melhoradas e um processo para sua preparação
BRPI0407106A (pt) Soluções de hemoglobina polimerizadas com quantidade reduzida de tetrâmero e método para preparação
PT986580E (pt) Misturas de oligossacarideos com actividade antitrombotica
BR9810616A (pt) Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer

Legal Events

Date Code Title Description
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/06/2012, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/03/99, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 24.03.2019